Table 2.
Types of immunotherapy used.
| Title | Number | Percentage |
|---|---|---|
| Pembrolizumab | 552 | 57.90% |
| Nivolumab | 309 | 32.40% |
| Atezolizumab | 77 | 8.10% |
| Durvalumab | 15 | 1.60% |
| Ipilimumab | 132 | 13.90% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.